These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6953275)

  • 1. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restorative effects of levamisole on cell-mediated immune responses following chemotherapy with aniline mustard in mice bearing ADJ-PC5 plasmacytoma.
    Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW
    Cancer Treat Rep; 1978 Nov; 62(11):1627-35. PubMed ID: 310338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
    Braun DP; Dray S
    Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
    Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
    Mokyr MB; Braun DP; Dray S
    Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
    [No Abstract]   [Full Text] [Related]  

  • 18. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
    Ben-Efraim S; Shoval S; Ophir R
    Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.
    Ben-Efraim S; Bocian RC; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1983; 15(2):101-7. PubMed ID: 6553510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.